Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis.

[1]  Stefan Neubauer,et al.  Myocardial Tissue Characterization Using Magnetic Resonance Noncontrast T1 Mapping in Hypertrophic and Dilated Cardiomyopathy , 2012, Circulation. Cardiovascular imaging.

[2]  R. Falk,et al.  Quantification of extracellular matrix expansion by CMR in infiltrative heart disease. , 2012, JACC. Cardiovascular imaging.

[3]  M. Robson,et al.  Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance , 2012, Journal of Cardiovascular Magnetic Resonance.

[4]  Marie-Pierre Jolly,et al.  Motion correction for myocardial T1 mapping using image registration with synthetic image estimation , 2012, Magnetic resonance in medicine.

[5]  P. Kellman,et al.  Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. , 2012, European heart journal.

[6]  H. Niessen,et al.  T1 mapping shows increased extracellular matrix size in the myocardium due to amyloid depositions. , 2012, Circulation. Cardiovascular imaging.

[7]  J. Moon,et al.  Updates in Cardiac Amyloidosis: A Review , 2012, Journal of the American Heart Association.

[8]  M. Robson,et al.  Cardiovascular magnetic resonance by non contrast T1-mapping allows assessment of severity of injury in acute myocardial infarction , 2012, Journal of Cardiovascular Magnetic Resonance.

[9]  S. K. White,et al.  Pre-contrast T1 mapping for detection of myocardial fibrosis in asymptomatic and symptomatic aortic stenosis , 2012, Journal of Cardiovascular Magnetic Resonance.

[10]  R. Falk,et al.  Cardiac Amyloidosis: A Treatable Disease, Often Overlooked , 2011, Circulation.

[11]  F. Weidemann,et al.  Echocardiographic evaluation of systolic and diastolic function in patients with cardiac amyloidosis. , 2011, The American journal of cardiology.

[12]  Stefan Neubauer,et al.  Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold , 2010, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[13]  M. Hayward,et al.  Equilibrium Contrast Cardiovascular Magnetic Resonance for the Measurement of Diffuse Myocardial Fibrosis: Preliminary Validation in Humans , 2010, Circulation.

[14]  R. Lang,et al.  Echocardiographic Evaluation of Cardiac Amyloid , 2010, Current cardiology reports.

[15]  Matthew W. Martinez,et al.  Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. , 2010, JACC. Cardiovascular imaging.

[16]  M. Desai,et al.  Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. , 2009, JACC. Cardiovascular imaging.

[17]  D. Pennell,et al.  Cardiovascular Magnetic Resonance and prognosis in cardiac amyloidosis , 2008, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[18]  Michael Jerosch-Herold,et al.  Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy. , 2008, American journal of physiology. Heart and circulatory physiology.

[19]  K. Klingel,et al.  Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. , 2008, Journal of the American College of Cardiology.

[20]  S. Neubauer,et al.  Evaluation and management of the cardiac amyloidosis. , 2007, Journal of the American College of Cardiology.

[21]  H. Kauczor,et al.  MR-Relaxometry of Myocardial Tissue: Significant Elevation of T1 and T2 Relaxation Times in Cardiac Amyloidosis , 2007, Investigative radiology.

[22]  J. Francis,et al.  Operator induced variability in left ventricular measurements with cardiovascular magnetic resonance is improved after training. , 2007, Journal of Cardiovascular Magnetic Resonance.

[23]  M. Salvadori,et al.  Renal involvement in systemic amyloidosis--an Italian retrospective study on epidemiological and clinical data at diagnosis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  R. Günther,et al.  Cardiac amyloidosis: MR imaging findings and T1 quantification, comparison with control subjects , 2007, Journal of magnetic resonance imaging : JMRI.

[25]  G. Merlini,et al.  Dangerous small B-cell clones. , 2006, Blood.

[26]  R. Falk.  Diagnosis and Management of the Cardiac Amyloidoses , 2005, Circulation.

[27]  F. Salvi,et al.  Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. , 2005, Journal of the American College of Cardiology.

[28]  R. Falk,et al.  Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.

[29]  A. Tajik,et al.  Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. , 2005, The American journal of cardiology.

[30]  R. Falk,et al.  Cardiovascular magnetic resonance in cardiac amyloidosis. , 2005, Circulation.

[31]  It Istituto Superiore di Sanit,et al.  Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from th 10th International Symposium on Amyloid an Amyloidosis, Tours, France, 18-22 April 2004 , 2005 .

[32]  T. Therneau,et al.  Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  E. McVeigh,et al.  Phase‐sensitive inversion recovery for detecting myocardial infarction using gadolinium‐delayed hyperenhancement † , 2002, Magnetic resonance in medicine.

[34]  R. Falk,et al.  The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. , 1998, QJM : monthly journal of the Association of Physicians.

[35]  R. Kyle,et al.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases. , 1995, Seminars in hematology.

[36]  M. Pepys,et al.  Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. , 1990, The New England journal of medicine.

[37]  A. Ericsson,et al.  Magnetic Resonance Imaging in Primary Amyloidosis , 1987, Acta radiologica.